Stonebridge Financial Group LLC Raises Holdings in Stryker Corporation $SYK

Stonebridge Financial Group LLC boosted its position in Stryker Corporation (NYSE:SYK) by 16.2% during the second quarter, Holdings Channel.com reports. The fund owned 16,134 shares of the medical technology company’s stock after purchasing an additional 2,251 shares during the quarter. Stonebridge Financial Group LLC’s holdings in Stryker were worth $5,079,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. VanderPol Investments L.L.C. increased its stake in Stryker by 1.4% during the fourth quarter. VanderPol Investments L.L.C. now owns 2,084 shares of the medical technology company’s stock worth $732,000 after acquiring an additional 28 shares during the last quarter. KCM Investment Advisors LLC lifted its stake in shares of Stryker by 1.5% in the 4th quarter. KCM Investment Advisors LLC now owns 1,857 shares of the medical technology company’s stock valued at $653,000 after purchasing an additional 28 shares in the last quarter. Rossby Financial LCC grew its holdings in shares of Stryker by 6.6% during the 4th quarter. Rossby Financial LCC now owns 451 shares of the medical technology company’s stock worth $159,000 after purchasing an additional 28 shares during the period. Tcfg Wealth Management LLC increased its position in Stryker by 2.7% during the 3rd quarter. Tcfg Wealth Management LLC now owns 1,091 shares of the medical technology company’s stock worth $403,000 after purchasing an additional 29 shares in the last quarter. Finally, Mechanics Financial Corp raised its holdings in Stryker by 1.2% in the fourth quarter. Mechanics Financial Corp now owns 2,458 shares of the medical technology company’s stock valued at $864,000 after buying an additional 30 shares during the period. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Wall Street Analysts Forecast Growth

SYK has been the topic of a number of recent research reports. Deutsche Bank Aktiengesellschaft set a $315.00 price target on shares of Stryker in a research report on Friday, May 1st. Robert W. Baird set a $385.00 target price on shares of Stryker in a research note on Friday, May 1st. Royal Bank Of Canada reduced their target price on shares of Stryker from $435.00 to $420.00 and set an “outperform” rating on the stock in a report on Friday. Argus set a $370.00 price target on shares of Stryker in a research report on Thursday, July 9th. Finally, Wells Fargo & Company cut their price objective on Stryker from $456.00 to $418.00 and set an “overweight” rating on the stock in a research report on Friday, May 1st. One analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and five have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $386.28.

Stryker Stock Performance

NYSE:SYK opened at $340.73 on Tuesday. The firm has a 50-day moving average of $317.77 and a two-hundred day moving average of $334.62. The company has a debt-to-equity ratio of 0.59, a current ratio of 2.16 and a quick ratio of 1.33. The stock has a market cap of $130.62 billion, a P/E ratio of 35.31, a PEG ratio of 2.08 and a beta of 0.76. Stryker Corporation has a 1-year low of $281.00 and a 1-year high of $396.86.

Stryker (NYSE:SYK) last announced its earnings results on Thursday, July 30th. The medical technology company reported $3.69 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.49 by $0.20. The business had revenue of $6.59 billion for the quarter, compared to analyst estimates of $6.58 billion. Stryker had a return on equity of 23.63% and a net margin of 14.43%.The company’s revenue for the quarter was up 9.4% compared to the same quarter last year. During the same period in the previous year, the company earned $3.13 earnings per share. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. On average, research analysts expect that Stryker Corporation will post 15.01 earnings per share for the current fiscal year.

Stryker Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, July 31st. Shareholders of record on Tuesday, June 30th were given a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.0%. The ex-dividend date of this dividend was Tuesday, June 30th. Stryker’s dividend payout ratio is presently 36.48%.

Insider Activity

In related news, VP Robert S. Fletcher sold 4,544 shares of the company’s stock in a transaction on Thursday, May 28th. The shares were sold at an average price of $306.87, for a total value of $1,394,417.28. Following the sale, the vice president directly owned 10,582 shares of the company’s stock, valued at $3,247,298.34. This represents a 30.04% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP M Kathryn Fink sold 5,220 shares of the stock in a transaction on Monday, May 11th. The shares were sold at an average price of $283.85, for a total transaction of $1,481,697.00. Following the transaction, the vice president owned 13,137 shares in the company, valued at $3,728,937.45. This trade represents a 28.44% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 323,264 shares of company stock worth $100,659,489. 4.60% of the stock is currently owned by insiders.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.